TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult SCD patients with genotypes SS, SC, SB+, or SB-~Exclusion Criteria:~* Patients with sickle cell trait~* Allergic to both morphine sulfate and hydromorphone,~* Patients who have an explicit care plan that states they cannot be admitted to the hospital for pain control,~* Non-English speaking,~* Patients admitted for a medical complication,~* Record of \>24 ED visits in the prior 12 months,~* Children

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient Specific dose of Morphine Sulfate or Hydromorphone (Type: EXPERIMENTAL): A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment protocols will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous). Dosage and frequency will be based on a patient's prior treatment history.
- Standard dose of Morphine Sulfate or Hydromorphone (Type: ACTIVE_COMPARATOR): A standardized analgesic protocol (based on recent NHLBI recommendations) for use in the ED to manage VOC crises. Treatment protocol will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous), with dosage based on weight. Repeat doses of opioids may be administered every 20-30 minutes as needed, although dosage will be maintained or provided at no more than 25% above the initial dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~MAIN PART:~1. Healthy Japanese male and female adult participants aged \>= 20 years of age at the time of signing of informed consent.~2. Participant who completed 2 doses primary vaccinations with another specified mRNA vaccine which is available in Japan 6 to 12 months prior to the trial vaccination.~   EXTENSION PART:~3. Participants who received the first trial vaccination at least 5 months earlier and are currently enrolled in the Main Part (ie, not have withdrawn or discontinued early).~Exclusion Criteria:~MAIN PART:~1. Participants who received any other SARS-CoV-2 vaccine (except for the specified mRNA vaccine) or other experimental novel coronavirus vaccine prior to the trial.~2. Participant who received a booster vaccination (i.e. 3rd dose)~3. Participants who have close contact of anyone known to have COVID-19 within 14 days prior to the trial vaccination.~4. Participants who were tested positive for SARS-CoV-2 prior to the trial.~5. Participants who have traveled outside of Japan in the 30 days prior to the trial participation.~6. Participants with a clinically significant active infection or oral temperature \>= 38 degree Celsius within 3 days of the intended date of the first single booster vaccination.~7. Participants with body mass index (BMI) greater than or equal to 30 kg/m\^2 (BMI= weight in kg/ height in meters\^2)~   EXTENSION PART:~8. Participants with a clinically significant active infection or oral temperature \>=38 degree Celsius within 3 days of the intended date of the second single booster vaccination.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TAK-019 Main Part (Type: EXPERIMENTAL): TAK-019 0.5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm
- TAK-019 Extension Part (Type: EXPERIMENTAL): TAK-019 0 .5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm. The participants who received the first single booster vaccination of TAK-019 in the main part and remained in study follow-up at least 5 months will receive a second single booster vaccination of TAK-019 by intramuscular injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adrenal insufficiency~Exclusion Criteria:~* Exclusion criteria were adrenocortical carcinoma and congenital adrenal hyperplasia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Conventional steroid treatment (Type: EXPERIMENTAL): Cortisone acetate and hydorocortisone will be administered in two daily doses
- Dual-release hydrocortisone (Type: EXPERIMENTAL): Dual-release hydrocortisone will be administered once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neuromuscular Block in Laryngeal Mask Airway(LMA) Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 year~* american society of anesthesiologist status 1-2~* elective general anesthesia~Exclusion Criteria:~* known or predicted difficult airway~* recent sore throat~* mouth opening less than 2.5 cm~* at risk of aspiration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- group N (Type: ACTIVE_COMPARATOR): Anesthesia is induced with propofol and remifentanil and LMA is inserted by the standard technique according to eht manufacturer's instruction. Rocuronium is administered for the operation.
- group R (Type: ACTIVE_COMPARATOR): Anesthesia is induced with a propofol and remifentanil and rocuronium 0.06 mg/kg is injected. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Desogestrel-containing COCP Pharmacokinetic Validation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy females aged 18-45 years~* Body-mass index ≥18.5kg/m2~* Willing to abstain from medications and supplements known to induce/inhibit CYP3A4 during the study~* Normal blood pressure measurement at screening (systolic \<140mmHg, diastolic \<90mmHg)~* Negative urine pregnancy test at screening~Exclusion Criteria:~* Currently taking any known CYP3A4 inducers/inhibitors~* Medical conditions that affect liver function (e.g. hepatitis, cirrhosis)~* Any contraindications to estrogen-containing contraception (based on any category 3 or 4 recommendations from the CDC MEC guidelines)~* Use of an injectable contraceptive method within the last 6 months or current use of an ENG contraceptive implant~* Childbirth within the last 6 months~* Known allergy or insensitivity to combined oral contraceptive pills

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Overall Cohort (Type: EXPERIMENTAL): Combined oral contraceptive pill containing 0.15mg desogestrel and 0.03mg ethinyl estradiol for 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers~* Subjects aged 18 - 45 years~* Subjects weighing ≥ 50.0 kg and ≤ 100.0 kg~* Subjects with a body mass index (BMI) ≥ 19.0 and ≤ 26.0 kg/m2~Exclusion Criteria:~* Subjects with evidence or history of clinically significant disease~* Subjects with a history of previous cancer~* Subjects with a history of hypertension, or abnormal blood pressure at screening/baseline measurements (systolic blood pressure \> 140 mmHg and/or diastolic blood pressure \> 90 mmHg confirmed by a repeat measurement on the same day)~* Subjects with a history of blood donation 3 months before study drug infusion~* Subjects with a history of exposure to antibodies 12 months before study drug infusion~* Subjects with previous exposure to anti-VEGF therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- LY01008 (Type: EXPERIMENTAL): Single intravenous injection of LY01008 3 mg/kg for 90 min(±1 min).
- Avastin (Type: ACTIVE_COMPARATOR): Single intravenous injection of Avastin 3 mg/kg for 90 min(±1 min).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pediatric and adult patients with a diagnosis of ALL or LBL.~2. Have had an allergic reaction to a long-acting E. coli-derived asparaginase OR have silent inactivation.~3. Have 1 or more courses of E. coli-derived asparaginase remaining in his/her treatment plan.~4. Patients must have, in the opinion of the Investigator, fully recovered from their prior allergic reaction to E. coli-derived asparaginase.~Exclusion Criteria:~1. Have previously received asparaginase Erwinia chrysanthemi or JZP-458.~2. Have relapsed ALL or LBL.~3. Are concurrently receiving another investigational agent and/or treated with an investigational device at the same time as JZP-458 (within 48 hours) during Course 1 of JZP-458.~4. Have a history of ≥ Grade 3 pancreatitis.~5. Prior history of asparaginase-associated ≥ Grade 3 hemorrhagic event or asparaginase-associated thrombus requiring anticoagulation therapy, excluding catheter-related thrombotic events.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JZP-458 (Type: EXPERIMENTAL): Part A (IM JZP-458) of the study will have 2 IM cohorts:~* Cohort 1: a JZP-458 repeat dose/confirmatory cohort; a final IM JZP-458 dose level will be selected, and~* Cohort 2: an expansion cohort to confirm the efficacy and safety of the final IM JZP-458 dose level and schedule~Part B (IV JZP-458 Dose Confirmation) will be conducted to define the optimal dose of the IV administration of JZP-458 for further study in ALL/LBL patients as a repeated dose.~Additional courses of JZP-458 (IM or IV depending on patient's allocation at study enrollment) will be administered based on each patient's original treatment plan for as long as the patient derives clinical benefit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~\* Adenocarcinoma of the prostate.~Exclusion Criteria:~* Previous prostate cancer treatment such as chemotherapy and/or pelvic radiation.~* Active inflammatory bowel disease (diverticulitis, Crohn's disease or ulcerative colitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease not affecting the rectum are allowed.)~* History of hip replacement.~* Prior intrapelvic surgery. This includes the following:~* Transrectal or rectal surgery other than polypectomy or hemorrhoid removal or banding~* Transabdominal pelvic surgery~* Bladder surgery~* Prior myocardial infarction (MI) or congestive heart failure (CHF).~* Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High-risk arm A (HR-A) (Type: EXPERIMENTAL): \< 15% risk of + lymph nodes (LN)
- HR-B (Type: EXPERIMENTAL): \> 15% risk of + LN

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of DSM-IV ADHD~* Score of equal or more than 2 on at least six of nine items in at least one of the subscales of the Connor´s Adult ADHD Rating Scale (CAARS-INV)~* Score of equal or more than 4 (at least moderate severity) on the Clinical Global Impressions-Severity (CGI-S) test~Exclusion Criteria:~* Current DSM-IV Axis I psychiatric disorder (other than ADHD)~* Current user of cigarettes or other nicotine-containing product.~* Slow metabolizers as indicated by CYP2D6 genotyping.~* Use of drugs affecting cognitive function within 8 weeks prior to enrollment visit or intended use during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CardioMEMS HF System Post Approval Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NYHA class III heart failure~* At least 1 heart failure hospitalization within previous 12 months~* Patients with reduced LVEF heart failure should be receiving a beta blocker for 3 months and an ACE-I or ARB for one month unless in the investigator's opinion, the patient is intolerant to beta blockers, ACE-I or ARB~* BMI ≤ 35. Patients with BMI \>35 will require their chest circumference to be measured at the axillary level. If \> 65 inches the patient will not be eligible for the study.~* Pulmonary artery branch diameter ≥ 7mm - (implant target artery - assessed during the right heart catheterization)~Exclusion Criteria:~* Active infection~* History of recurrent (\> 1) pulmonary embolism or deep vein thrombosis~* Inability to tolerate a right heart catheterization~* A major cardiovascular event (e.g., myocardial infarction, open heart surgery, stroke, etc.) within previous 2 months~* Cardiac resynchronization device (CRT) implanted within previous 3 months~* Glomerular Filtration Rate (GFR) \< 25 ml/min (obtained within 2 weeks of implant) who are non-responsive to diuretic therapy or who are on chronic renal dialysis~* Congenital heart disease or mechanical right heart valve~* Likely to undergo heart transplantation or VAD within the next 6 months~* Known coagulation disorders~* Hypersensitivity or allergy to aspirin, and/or clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CardioMEMS HF System Group (Type: None): Patients implanted with a CardioMEMS HF System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Exacerbation of COPD as defined by the presence of at least 2 of the following: change in baseline dyspnea, cough, or sputum quantity or purulence.~Exclusion Criteria:~* Signs of severe exacerbation (arterial pH \< 7.26 or PaCO2 \> 9.3 kPa)~* History of asthma~* Significant or unstable co-morbidity~* Participated in another study 4 weeks before admission~* Previously randomized to this study~* Known hypersensitivity to prednisolone~* Inability to give written informed consent~* Radiological diagnosis of pneumonia~* Estimated survival of less than 6 months due to severe comorbidity~* Use of glucocorticoid within 1 month before admission

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Personalized variable dose of glucocorticoids arm (Type: EXPERIMENTAL): Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, Inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), Long-Acting Muscarinic Antagonists(LAMA), short-acting beta2-agonist (SABA), and other physical treatments.
- Fixed dose of glucocorticoids arm (Type: OTHER): Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Child born at less than or equal to 29 completed weeks' gestation;~2. Child between 18 months, 0 days and 38 months, 30 days old chronological age;~3. Child admitted to NICU and/or had a Neonatology Clinic follow up visit scheduled.~4. Child showing some autistic symptoms;~5. Child between the 5th and 95th percentiles (per WHO growth chart) for weight at his/her most recent hospital visit;~6. English spoken in the home, demonstrate ability to communicate in English well-enough to understand study, informed consent, and study questionnaires; and~7. Have informed consent on file.~Exclusion Criteria:~1. Consume LCPUFA supplement drops, chews, powders, Pediasure, or fatty fish more than 2x per week;~2. Unable to tolerate venipuncture;~3. Any major malformation that would preclude participation;~4. Cerebral Palsy (quadriparesis only);~5. Deafness;~6. Blindness;~7. Bleeding disorder;~8. Type I diabetes;~9. Fragile X Syndrome, Rett Syndrome, Angelman Syndrome, Tuberous Sclerosis;~10. Non febrile seizure in the last month without a clear and resolved etiology;~11. Feeding problem that may inhibit full participation;~12. Known fish allergy;~13. Known canola/rapeseed allergy or sensitivity; or~14. Recorded score of \<70 on Bayley Cognitive Section within the past year.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 39 Months
- Healthy Volunteers: f

Study Arms:
- LCPUFA Oil Supplement (Type: EXPERIMENTAL): EPA + DHA + GLA + OA oil supplement
- Canola Oil Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female outpatients between the ages of 18 and 48 who are:~  * Menstruating~ * Meet criteria for moderate to severe PMS~ * Report PMS symptoms for at least 9 our of the 12 months prior to screening; 4) \*Are using an adequate method of birth control.~Exclusion Criteria:~* Any candidate who:~  * Fulfills MINI (DSM-IV) criteria for a serious AXIS 1 disorder~ * Fulfills DSM-IV criteria during the charting phase consistent with a diagnosis of psychotic disorder, bipolar disorder or major depressive disorder~ * Has a severe, co-existing condition that, in the investigator's opinion, renders the patient unsuitable for the study~ * Poses a significant risk of suicide~ * Takes ongoing medication that could treat PMS symptoms~ * Has a history of hypersensitivity or adverse reaction to fluoxetine or calcium~ * Is lactating, pregnant or is planning to become pregnant during the course of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: ACTIVE_COMPARATOR): Fluoxetine
- II (Type: ACTIVE_COMPARATOR): Calcium
- III (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete